These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 10692642)

  • 1. Parameters affecting the efficacy of a sustained release polymeric implant of leuprolide.
    Ravivarapu HB; Moyer KL; Dunn RL
    Int J Pharm; 2000 Jan; 194(2):181-91. PubMed ID: 10692642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained activity and release of leuprolide acetate from an in situ forming polymeric implant.
    Ravivarapu HB; Moyer KL; Dunn RL
    AAPS PharmSciTech; 2000 Feb; 1(1):E1. PubMed ID: 14727850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained suppression of pituitary-gonadal axis with an injectable, in situ forming implant of leuprolide acetate.
    Ravivarapu HB; Moyer KL; Dunn RL
    J Pharm Sci; 2000 Jun; 89(6):732-41. PubMed ID: 10824131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymer and microsphere blending to alter the release of a peptide from PLGA microspheres.
    Ravivarapu HB; Burton K; DeLuca PP
    Eur J Pharm Biopharm; 2000 Sep; 50(2):263-70. PubMed ID: 10962237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended release peptide delivery systems through the use of PLGA microsphere combinations.
    Burton KW; Shameem M; Thanoo BC; DeLuca PP
    J Biomater Sci Polym Ed; 2000; 11(7):715-29. PubMed ID: 11011769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An eight-month clinical study of LA-2575 30.0 mg: a new 4-month, subcutaneous delivery system for leuprolide acetate in the treatment of prostate cancer.
    Sartor O; Dineen MK; Perez-Marreno R; Chu FM; Carron GJ; Tyler RC
    Urology; 2003 Aug; 62(2):319-23. PubMed ID: 12893343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydrophobic ion pair formation between leuprolide and sodium oleate for sustained release from biodegradable polymeric microspheres.
    Choi SH; Park TG
    Int J Pharm; 2000 Aug; 203(1-2):193-202. PubMed ID: 10967441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The nature of peptide interactions with acid end-group PLGAs and facile aqueous-based microencapsulation of therapeutic peptides.
    Sophocleous AM; Desai KG; Mazzara JM; Tong L; Cheng JX; Olsen KF; Schwendeman SP
    J Control Release; 2013 Dec; 172(3):662-70. PubMed ID: 24021356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preparation of three-month depot injectable microspheres of leuprorelin acetate using biodegradable polymers.
    Okada H; Doken Y; Ogawa Y; Toguchi H
    Pharm Res; 1994 Aug; 11(8):1143-7. PubMed ID: 7971715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stability of poly(D,L-lactide-co-glycolide) and leuprolide acetate in in-situ forming drug delivery systems.
    Dong WY; Körber M; López Esguerra V; Bodmeier R
    J Control Release; 2006 Oct; 115(2):158-67. PubMed ID: 16963145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of the poly(lactide-co-glycolide) type on the leuprolide release from in situ forming microparticle systems.
    Luan X; Bodmeier R
    J Control Release; 2006 Jan; 110(2):266-272. PubMed ID: 16300851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preparation, characterization and in vivo evaluation of 120-day poly(D,L-lactide) leuprolide microspheres.
    Woo BH; Kostanski JW; Gebrekidan S; Dani BA; Thanoo BC; DeLuca PP
    J Control Release; 2001 Aug; 75(3):307-15. PubMed ID: 11489318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of biodegradable in situ implant and microparticle injectable formulations for sustained delivery of haloperidol.
    Ahmed TA; Ibrahim HM; Ibrahim F; Samy AM; Kaseem A; Nutan MT; Hussain MD
    J Pharm Sci; 2012 Oct; 101(10):3753-62. PubMed ID: 22753324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Formulation and characterization of injectable poly(DL-lactide-co-glycolide) implants loaded with N-acetylcysteine, a MMP inhibitor.
    Desai KG; Mallery SR; Schwendeman SP
    Pharm Res; 2008 Mar; 25(3):586-97. PubMed ID: 17891553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biocompatibility of poly (DL-lactide-co-glycolide) microspheres implanted into the brain.
    Emerich DF; Tracy MA; Ward KL; Figueiredo M; Qian R; Henschel C; Bartus RT
    Cell Transplant; 1999; 8(1):47-58. PubMed ID: 10338275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biodegradable PLGA microspheres as a sustained release system for a new luteinizing hormone-releasing hormone (LHRH) antagonist.
    Du L; Cheng J; Chi Q; Qie J; Liu Y; Mei X
    Chem Pharm Bull (Tokyo); 2006 Sep; 54(9):1259-65. PubMed ID: 16946531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initial Leuprolide Acetate Release from Poly(d,l-lactide-
    Li Z; Mu H; Larsen SW; Jensen H; Østergaard J
    Mol Pharm; 2020 Dec; 17(12):4522-4532. PubMed ID: 33164519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolonged anti-inflammatory action of DL-lactide/glycolide copolymer nanospheres containing betamethasone sodium phosphate for an intra-articular delivery system in antigen-induced arthritic rabbit.
    Horisawa E; Hirota T; Kawazoe S; Yamada J; Yamamoto H; Takeuchi H; Kawashima Y
    Pharm Res; 2002 Apr; 19(4):403-10. PubMed ID: 12033371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic (60-week) toxicity study of DUROS leuprolide implants in dogs.
    Cukierski MJ; Johnson PA; Beck JC
    Int J Toxicol; 2001; 20(6):369-81. PubMed ID: 11797819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. One-month release injectable microcapsules of a luteinizing hormone-releasing hormone agonist (leuprolide acetate) for treating experimental endometriosis in rats.
    Okada H; Heya T; Ogawa Y; Shimamoto T
    J Pharmacol Exp Ther; 1988 Feb; 244(2):744-50. PubMed ID: 3126294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.